Spokane-based pharmaceutical manufacturer Selkirk Pharma Inc. has named Colleen Dixon as its new CEO, the company announced in a release earlier today, July 9. 

Dixon, who has more than 30 years of experience in the pharmaceutical industry, previously served as vice president of program management at Selkirk. Before joining the Spokane company, she worked as head of biopharmaceutical project management at AstraZeneca. She also has held senior leadership positions at Baxter Biopharma Solutions, and Eli Lilly & Co., according to the release

She replaces Patrick Haffey, the company's founder and CEO and chairman for the past six years. 

An attempt to reach Selkirk Pharma for additional information was unsuccessful. 

Located at 9119 W. Granite on the West Plains, Selkirk Pharma specializes in injectable drugs, including vaccines and biological therapeutics.